Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sorafenib in the First Line Treatment of Advanced Hepatocellular Carcinoma With Child-Pugh Liver Function Class B: Multicentre Phase 3 Randomized Trial

NCT01405573 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.

NCT NCT01405573
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01405573 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sorafenib in the First Line Treatment of Advanced Hepatocellular Carcinoma With Child-Pugh Liver Function Class B: Multicentre Phase 3 Randomized Trial
Lead sponsor
National Cancer Institute, Naples
Phase
Phase 3
Overall status
Terminated
Start date
July 31, 2011
Completion date
March 31, 2017
Enrollment
35 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

advanced adult hepatocellular carcinoma